Abstract: Human cytomegalovirus (HCMV) is a leading cause of morbidity and mortality in immunocompromised hosts. In immunocompetent hosts, HCMV is associated with chronic inflammatory diseases including atherosclerosis. Monocytes and macrophages are proposed to play key roles in HCMV dissemination to host tissue, and their infection provides a biological link between the lifecycle of HCMV and disease pathology. We hypothesize that viral spread occurs via a mechanism in which infected peripheral blood monocytes, which are nonpermissive for viral replication, extravasate into host tissue and subsequently differentiate into permissive macrophages. Supporting this hypothesis, we recently showed that HCMV specifically induced the differentiation of monocytes into macrophages that become permissive for viral replication. To expand our understanding of HCMV pathogenesis, we next examined monocyte activation and migration, the first events in viral pathogenesis. We show here that HCMV up-regulates phosphatidylinositol 3,4,5 triphosphate kinase [PI(3)K] activity and that this increased PI(3)K activity is essential for infected monocyte-transendothelial migration. This increase in migration occurs through the up-regulation of cell motility in a PI(3)K-dependent process. Last, we show that these activated monocytes express a number of inflammatory mediators via PI(3)K signaling. We propose that the up-regulation of monocyte migration and immune mediators by HCMV infection is required for the hematogenous dissemination of the virus and as a consequence, could promote chronic inflammatory diseases associated with HCMV infection. J. Leukoc. Biol. 76: 65-76; 2004.
INTRODUCTION
Human cytomegalovirus (HCMV) is a ubiquitous ␤-herpesvirus that infects greater than 60% of the U.S. population [1, 2] .
HCMV infection usually occurs early in life and results in the establishment of life-long viral persistence [3] . Traditionally, HCMV is considered a pathogen that causes severe disease in the immunocompromised. HCMV is one of the most common, opportunistic infections in AIDS patients [4, 5] and organtransplant recipients [6] , where it causes significant morbidity and mortality. HCMV is also the leading cause of congenital central nervous system damage in neonates [7] . In immunocompetent hosts, HCMV infection is generally asymptomatic, although in some patients, it can cause infectious mononucleosis [3] . However, more recent evidence shows that HCMV infection is associated with chronic inflammatory diseases. Specifically, HCMV infection is linked to the development and severity of the cardiovascular diseases atherosclerosis [8 -12] and coronary restenosis [9, 13] .
Because of our laboratory's interest in HCMV pathogenesis, we began an investigation into the potential mechanisms by which HCMV infection of monocytes promotes chronic inflammation. We have evidence demonstrating that HCMV infection of monocytes results in their aberrant activation and the induction of an inflammatory phenotype that is consistent with HCMV pathogenesis. We showed that HCMV infection of monocytes induces nuclear factor-B activation, which in turn promotes inflammatory cytokine production [14] . Furthermore, we demonstrated that this viral induction of inflammatory mediators occurs through viral binding alone [14] , suggesting that HCMV binding to target cells mimics cytokine signaling by activating cellular signaling pathways through a receptor ligand-mediated process. These findings raise the following question: What is the benefit of HCMV-induced monocyte activation and inflammatory cytokine induction for the HCMV lifecycle in the host?
We hypothesized that HCMV uses an inflammatory response to activate newly infected monocytes in the peripheral blood and drive their transendothelial migration as a mechanism of viral dissemination to host tissue, an essential element for the viral lifecycle in the infected host and in a broader sense, in the human population [15] . Such a monocyte-driven mechanism of HCMV spread fits with observations that infected macrophages are found in the tissue of seropositive hosts following viremia [15] [16] [17] [18] [19] . Furthermore, monocytes are the primary cell type infected during viremia [15, 20, 21] and the predominant infiltrating cell type found in infected organs [22] . Monocytes have also been shown to be a source of viral latency [21, [23] [24] [25] [26] [27] .
To test our hypothesis, we examined if HCMV infection activates monocytes to promote monocyte-to-macrophage differentiation, viral replication, and migration. We demonstrated that HCMV infection of monocytes, which are nonpermissive for viral gene expression and replication, promotes their differentiation into macrophages permissive for viral replication, thus providing a mechanism of viral replication and spread in tissue [28] . In addition, we documented that HCMV infection of monocytes promotes monocyte extravasation as a potential mechanism of viral spread from the peripheral blood to host tissue during viremia [28] , a finding that is consistent with recent studies in animal models of cytomegalovirus (CMV) pathogenesis [29 -32] . However, in this initial study, we did not address the viral mechanism for the induction of monocyte differentiation and migration. We propose that the activation of monocytes by HCMV through cellular signaling pathways is necessary to drive their migration out of host tissue, to allow for viral replication, and to promote viral spread and the establishment of life-long persistence. A consequence of this aberrant monocyte activation and migration would be the migration of activated monocytes into the subendothelial space of vessels and peripheral tissues, a biological event that could promote chronic inflammatory disease such as atherosclerosis.
Atherosclerosis is a chronic inflammatory disease, which at the cellular level, involves the migration of activated monocytes from the peripheral blood into the subendothelial space and their production of inflammatory cytokines and chemokines [33, 34] . The aberrant activation and migration of monocytes are critical to the initiation and progression of atherosclerotic disease and represent the first recognizable events detected during atherosclerotic plaque development [35] [36] [37] [38] . Migrating activated monocytes contribute to atherogenesis through their production of proinflammatory cytokines and chemokines, which promote additional leukocyte recruitment into plaques [39 -41] , endothelial and smooth muscle cell proliferation [42] [43] [44] , and atherosclerotic plaque rupture and thrombus formation [45] [46] [47] . Together, these findings point to a central role monocytes play in atherosclerotic disease. As the effects of HCMV infection of monocytes appear to mimic the biology of monocytes in atherosclerotic plaques, our findings may provide a biological link between the lifecycle of HCMV and diseases associated with infection.
We hypothesize that viral-mediated, cellular activation is the driving force behind the HCMV-induced changes in monocyte function that we observed. We suggest that HCMV usurps cellular signal-transduction pathways in monocytes to allow viral spread to host tissues and in so doing, acts as a promoter of inflammation in the host. As HCMV-induced monocyte migration is critical for viral spread [28] and would provide a biological mechanism to account for the role of HCMV in atherogenesis [12] , we initiated a study to focus on the cellular pathway(s) activated during HCMV infection that promotes monocyte migration. Here, we report that HCMV up-regulates phosphatidylinositol 3,4,5 triphosphate kinase [PI(3)K] activity in monocytes and provide the first evidence that this viralinduced PI(3)K activity is required for monocyte-transendothelial migration following HCMV infection. Furthermore, we showed that the increased PI(3)K activity induces monocyte motility and regulates the expression of inflammatory chemokines and chemokine receptors related to monocyte migration and implicated in atherogenesis. Together, our data describe a novel viral mechanism that makes biological "sense" for HCMV; aberrant PI(3)K activation would allow newly infected peripheral blood monocytes to infiltrate host tissue, differentiate into macrophages, and subsequently, establish the persistent infection seen in the tissue of seropositive hosts [15] . This abnormal, HCMV-induced monocyte migration could also promote chronic inflammatory diseases by increasing monocyte infiltration into sites such as atherosclerotic plaques, which with the subsequent release of inflammatory mediators and virus, would exacerbate the disease.
MATERIALS AND METHODS

HCMV culture and infection
Methods for the culturing of our HCMV Towne strain (passage [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] in human embryonic lung (HEL) fibroblasts have been described previously [14, 48, 49] . Prior to infection, HEL fibroblasts were cultured in minimum essential media (MEM; Cellgro by Mediatech, Herndon, VA) supplemented with 10% fetal bovine serum (FBS; Gemini, Woodland, CA) at 37°C with 5% CO 2 . Fibroblasts were then infected with HCMV at a multiplicity of infection (M.O.I.) of 0.05 and incubated in MEM supplemented with 4% heat-inactivated FBS. HCMV was harvested from infected fibroblasts between days 6 and 12 postinfection, purified on a 0.5 M sucrose gradient as described previously [14, 28] , and resuspended in RPMI (Cellgro). Gradient-purified virus was used to infect monocytes at a M.O.I. of 15 [28] . Mock-infected cell treatment involved adding RPMI alone to cells at a volume equivalent to the virus treatment.
Monocyte isolation, treatment, and culture
Human peripheral blood monocytes were purified by double-density gradient centrifugation [14, 14, 50] . Whole blood was taken by venipuncture from HCMV-seronegative donors and centrifuged through a Ficoll Histopaque 1077 (Sigma Chemical Co., St. Louis, MO) gradient. The collected mononuclear cells were washed six times to remove platelets. The monocytes were then isolated by centrifugation through a Percoll (Pharmacia, Piscataway, NJ) gradient. This technique yields 3-5 ϫ 10 7 monocytes per donor at a purity of ϳ90%. Monocytes were pretreated nonadherently with the PI(3)K inhibitor LY294002 (25 or 50 M, Promega, Madison, WI), cytochalasin D (4 M, Promega), or the control drug solvent dimethyl sulfoxide (DMSO) for 1 h before HCMV infection, mock infection, or phorbol 12-myristate 13-acetate (PMA; 10 ng/ml, Sigma Chemical Co.) treatment as described above. Monocytes were then plated at the cell densities described in each experimental section and cultured in endotoxin-free RPMI supplemented with 10% human serum (Sigma Chemical Co.) at 37°C with 5% CO 2 . A dose response of LY294002 treatment revealed that 25 and 50 M LY294002 did not affect monocyte viability at 48 h post-treatment (data not shown). University Institutional Review Board and Health Insurance Portability and Accountability Act guidelines were followed for all experimental protocols.
were harvested in Laemmli sample buffer (Bio-Rad, Hercules, CA) at the indicated time-points and boiled for 10 min. Samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and were transferred to nitrocellulose (Immobilon-P, Millipore, Billerica, MA). Blots were blocked in a Tris-buffered saline with 0.1% Tween 20 and 0.1% gelatin and then incubated with an anti-Pan-Akt polyclonal antibody (Cell Signaling Technology, Beverly, MA), an anti-phospho-Akt (anti-p-Akt; Ser473) polyclonal antibody (Cell Signaling Technology), or an anti-actin polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 4°C. Blots were washed, incubated with a horseradish peroxidase (HRP)-conjugated anti-rabbit secondary antibody (Santa Cruz Biotechnology) or a HRP-conjugated anti-goat secondary antibody (Santa Cruz Biotechnology), and detected using the ECL Plus (Amersham Pharmacia Biotech, Piscataway, NJ) protocol.
Transendothelial migration assay
Transendothelial migration assays were performed using human dermal microvascular endothelial cells (HMECs) cultured on cell-culture inserts (BD Falcon, Bedford, MA) with an 8-m pore size in 24-well plates (Corning Costar, Cambridge, MA). HMECs were incubated and grown to confluence in endothelial growth medium-1 (Clonetics, Walkersville, MD) supplemented with 10% heat-inactivated FBS (Clonetics), hydrocortisone (1 g/ml, Clonetics), human epidermal growth factor (10 ng/ml, Clonetics), bovine brain extract (12 g/ml, Clonetics), and gentamicin sulfate amphotericin-B (Clonetics) at 37°C with 5% CO 2 . Monocytes were isolated and treated as described above. Treated monocytes were labeled with CellTracker Green 5-chloromethylfluorescein diacetate (Molecular Probes, Eugene, OR) according to the manufacturer's protocol. Monocytes were then washed and resuspended in RPMI supplemented with 10% human serum. The media within the transwells and the wells of the plate were removed and replaced with RPMI supplemented with 10% human serum. Monocytes (2.5ϫ10 4 ) were then plated per transwell and incubated at 37°C with 5% CO 2 . The cell-tracker dye alone had no effect on monocyte viability and cell migration nor did it interfere with HCMV infection (data not shown). Furthermore, the endothelial cells were viable for the entire course of our experiment and maintained their junctional integrity (data not shown). The ratios of cells undergoing diapedesis versus those cells that were stationary on the surface of the endothelial monolayer were determined by inverted fluorescence microscopy at 24 h post-addition of monocytes. Results are plotted as mean Ϯ SD of 15 random fields of view (200ϫ magnification) from three separate experiments using different human blood donors. The number of monocytes that had migrated completely through the endothelial monolayer and the cell culture insert was determined by inverted fluorescence microscopy at 96 h post-addition of monocytes. Results are plotted as mean Ϯ SEM of 30 random fields of view (200ϫ magnification) from three separate experiments using different human blood donors. The percentage of monocytes that had undergone total migration at 96 h out of the total number of monocytes added per transwell (input cells) was determined as follows. Transwells were removed from the 24-well plates, and monocytes adhered to the bottom of each well were incubated with versene (0.2 mg/ml EDTA, BioWhittaker, Wakersville, MD) for 1 h at 37°C. Monocytes were then removed from the wells by gentle scraping, washed, and counted with a hemocytometer to determine the total number of monocytes per well. Results are plotted as mean Ϯ SD of three counted wells per experimental arm. Statistical significance between experimental means (P value) was determined using Student's t-test.
F-actin staining
To stain for F-actin, monocytes were isolated and treated as described above, and 2.5 ϫ 10 4 monocytes were plated on 15 mm fibronectin-coated glass coverslips in 24-well plates and incubated for 24 h. As a negative control, monocytes were treated with cytochalasin D (4 M, Promega) for 30 min before cell fixation and staining. Following 24 h of incubation, monocytes were fixed with 1% paraformaldehyde/2% sucrose for 15 min and subsequently stained with Alexa Fluor 594 phalloidin (Molecular Probes) and 4Ј,6-diamidino-2-phenylindole (DAPI; Molecular Probes) according to the manufacturer's protocol. Images of monocytes were captured using a fluorescent microscope (1000ϫ magnification).
Phagokinetic track motility assay
Phagokinetic track motility assays were performed using a modified protocol of Scott et al. [51] . To prepare colloidal gold-coated coverslips, 15 mm glass coverslips were heated in a 300-bloom gelatin solution (0.5 g in 300 ml, Sigma Chemical Co.) at 90°C for 10 min and dried at 70°C for 45 min. Colloidal gold suspensions were prepared by mixing 11 ml endotoxin-free water (Sigma Chemical Co.), 6 ml Na 2 CO 3 (36.5 mM), and 1.8 ml AuHCl 4 (14.5 mM, Fisher Scientific, Pittsburgh, PA). The solution was brought to a rapid boil, and 1.8 ml 0.1% formaldehyde was added immediately to the solution. The suspension (4 ml) was added to each coverslip while still hot and incubated at 37°C for 1 h. Coverslips were washed in calcium-and magnesium-free saline and transferred to 24-well plates containing RPMI supplemented with 10% human serum. Monocytes were isolated and treated as described above, and 500 monocytes were added to each well. After 6 h of incubation, monocytes were fixed for 15 min in calcium-and magnesium-free phosphate-buffered saline containing 1% paraformaldehyde and mounted on slides. Track images of individual cells were video-captured at 400ϫ magnification. The average area cleared per cell out of 50 cells per sample was determined in square arbitrary units using Scion Image software (Scion Corporation, Frederick, MD). Results are plotted as mean Ϯ SEM of 50 cells. Statistical significance between experimental means (P value) was determined using Student's t-test.
Gene-chip analysis
Monocytes were isolated and treated as described above, and 2 ϫ 10 6 monocytes were plated per fibronectin-coated 100 mm dish. After 48 h of incubation, total RNA was harvested from 1 ϫ 10 7 monocytes (five plates) per experimental arm, purified using the Stat-60 RNA isolation kit (Tel-Test, Inc., Friendswood, TX), and converted into cRNA according to the manufacturer's instructions (Affymetrix, Santa Clara, CA). Affymetrix Human Genome U95Au2 arrays were hybridized, washed, and scanned according to the manufacturer's instructions (Affymetrix). Data were analyzed using Affymetrix Microarray Suite 4.0 software (Affymetrix) to determine signal intensity for each probe set. Table 1 represents gene products related to inflammation and migration, which were up-regulated twofold or greater in DMSO-pretreated, HCMV-infected monocytes compared with DMSO-pretreated, mock-infected monocytes and also down-regulated twofold or greater in LY294002-pretreated, HCMV-infected monocytes compared with DMSO-pretreated, HCMVinfected monocytes. Only those gene products that met these criteria in two separate experiments using monocytes isolated from two blood donors were included in Table 1 .
RNase protection assays
Monocytes were isolated and treated as described above, and 2 ϫ 10 6 monocytes were plated per fibronectin-coated 100 mm dish. After 48 h of incubation, total RNA was harvested from 1 ϫ 10 7 monocytes (five plates) per experimental arm and purified using the Stat-60 RNA isolation kit (Tel-Test). DMSO-pretreated mock-infected, LY294002-pretreated mock-infected, DMSO-pretreated HCMV-infected, and LY294002-pretreated HCMV-infected monocyte RNA was hybridized with an [␣ 32 P]uridine 5Ј-triphosphate (UTP)-labeled human cytokine multiprobe (hCM-8) template set (BD Biosciences, San Diego, CA) overnight according to the manufacturer's protocol. RNase protection assays were then performed with labeled RNA using the MultiProbe RNase protection assay system (BD Biosciences) according to the manufacturer's protocol. Briefly, samples were treated with RNase, and purified, protected probes were resolved on a denaturing polyacrylamide gel. The gel was dried, and radioactivity was quantified by phosphorimaging. Band intensities (see representation in Fig. 6B ) were determined using Quantity One image analysis software (Bio-Rad) and normalized to the respective L32 band intensities.
RESULTS
HCMV infection of monocytes up-regulates PI(3)K activity
The serine/threonine kinase Akt (also known as protein kinase B) is a principal downstream target of PI(3)K and is activated by phosphorylation in a PI(3)K-dependent manner [53] . To determine if HCMV infection of monocytes up-regulates PI(3)K activity, we compared by Western blot analyses the levels of Ser473 p-Akt and total Akt (Pan-Akt) between mock and infected monocytes in the presence or absence of the specific PI(3)K inhibitor LY294002 (Fig. 1A) . As a control for loading, total ␤-actin levels were assessed (Fig. 1A) . Levels of Pan-Akt and Ser473 p-Akt were determined by densitometry and expressed as a ratio of x/actin in arbitrary units (Fig. 1B) . Mock-infected monocytes exhibited a continual decrease in Ser473 p-Akt levels, and levels of p-Akt increased in infected monocytes out to 36 h post-infection. In mock and infected monocytes, a 1-h pretreatment of cells (before infection/adhesion) with LY294002 blocked phosphorylation of Akt, indicating that phosphorylation of Akt following HCMV infection of monocytes is PI(3)K-dependent. Mock and infected monocytes exhibited similar levels of total Akt expression at early times postinfection, although at later times postinfection, infected monocytes showed enhanced steady-state levels of Akt. Consistent with our previous reports that HCMV infection promotes monocyte activation and migration independent of viral gene expression [14, 28] , treatment of monocytes with replicationdefective, UV-inactivated HCMV also resulted in increased PI(3)K activity out to 36 h postinfection (data not shown). Together, these data suggest that HCMV infection of monocytes results in a sustained activation of PI(3)K.
HCMV-induced monocyte-transendothelial migration is dependent on PI(3)K activity
We previously showed that HCMV infection induced monocyte diapedesis [28] ; however, in this initial study, we did not address the mechanism by which HCMV alters monocyte migration. Because of the central role monocyte migration plays in HCMV pathogenesis, we next addressed if HCMV-induced PI(3)K activation served as the mechanism to account for this increased migration activity. We focused here on determining the role of PI(3)K in HCMV-induced monocyte-transendothelial migration, as PI(3)K has been reported to regulate monocyte motility and migration induced by chemotactic factors [54, 55] . We hypothesized that HCMV-induced PI(3)K activation initiates monocyte diapedesis. To test this hypothesis, CellTracker Green (Molecular Probes)-labeled monocytes were pretreated with the PI(3)K inhibitor LY294002 (25 M and 50 M) or with DMSO as a control and then mock-infected or HCMV-infected. As a positive control, PMA-treated monocytes were also used in this assay and were likewise treated with LY294002 (50 M). Treated monocytes were then subjected to transendothelial migration assays using a transwell system containing a confluent monolayer of HMECs. No chemoattractants were added to the transwells in these assays to effectively mimic the in vivo biology of HCMV-mediated monocyte migration. That is, peripheral blood monocytes must be able to respond to a primary HCMV infection in such a way that they migrate into the host tissue in the absence of a chemotactic gradient. Once infected, monocytes would reach the tissue, and chemokine release could recruit additional monocytes to sites of infection, as discussed later in Results. The ratios of monocytes undergoing diapedesis through the endothelial monolayers versus those that were stationary on the monolayer surface were determined by inverted fluorescent microscopy at 24 h postaddition of monocytes to the upper chamber of the transwell. We are defining monocytes undergoing diapedesis as those cells that are spread out on top of the endothelial monolayer and show cytoplasmic protrusions, partially above and partially below the monolayer, or underneath the monolayer as originally defined by Ronald et al. [56] . Stationary monocytes were defined as those monocytes that were nonadherent to the monolayer or were adherent on the top of the monolayer and had a rounded, ball-like morphology [56] . DMSO-pretreated HCMV-infected monocytes had a significantly higher ratio of migrating to stationary monocytes when compared with mockinfected monocytes at 24 h postinfection (Fig. 2) . Furthermore, the percentage of DMSO-pretreated HCMV-infected monocytes undergoing diapedesis was comparable with PMA-treated monocytes (Fig. 2) . When PI(3)K activity was inhibited with LY294002 before HCMV infection or PMA treatment, viralinduced and PMA-induced monocyte diapedesis were significantly reduced (PϽ0.01) and were similar to levels seen with mock-infected monocytes (Fig. 2) . Pretreating mock-infected monocytes with LY294002 had no significant effect on monocyte diapedesis. These data suggest that HCMV infection of monocytes initiates migration in a PI(3)K-dependent manner.
At 96 h postaddition of monocytes to the transwells, the average number of monocytes per field of view that had undergone total migration was determined. Total migration represents monocytes that have migrated through the endothelial cell monolayers and the pores of the transwell inserts and into the bottom chamber. HCMV-infected monocytes treated with the DMSO control alone exhibited a fivefold increase in total migration in comparison with mock-infected monocytes (Fig.  3A) . When monocytes were pretreated with 25 and 50 M LY294002 before HCMV infection, total migration was reduced in a dose-dependent manner (Fig. 3A) . LY294002 (50 M) pretreatment reduced the total migration of HCMV-infected and PMA-treated monocytes to the level exhibited by mock-infected monocytes (Fig. 3A) . LY294002 pretreatment of mock-infected monocytes had no significant effect on total migration (Fig. 3A) . To ascertain the percentage of input monocytes that had undergone total migration, monocytes from the different treatment groups were removed from the bottom of the well at 96 h postaddition by removing cells with versene treatment and gentle scraping and subsequently counting the total number of cells present in each experimental arm. DMSOpretreated HCMV-infected monocytes and PMA-treated monocytes exhibited a significant increase (PϽ0.01) in the percentage of input cells positive for total migration in comparison with DMSO-pretreated mock-infected monocytes (Fig. 3B) . LY294002 (50 M) pretreatment of HCMV-infected and PMAtreated monocytes reduced the percentage of input monocytes that had undergone total migration to levels comparable with DMSO-pretreated mock-infected monocytes (Fig. 3B) . Input HCMV-infected monocytes (62.5%) had undergone total migration, and only 20% of input LY294002-pretreated HCMVinfected monocytes underwent total migration (Fig. 3B) . Pretreating mock-infected monocytes with LY294002 had no significant effect on the percentage of input mock-infected monocytes that had undergone total migration (Fig. 3B) . Use of wortmannin, an alternative PI(3)K inhibitor, blocked HCMVinduced monocyte diapedesis and total migration to the same degree as LY294002, thus confirming the role of PI(3)K in these HCMV-induced events (data not shown). Together, these data suggest that the initial steps of HCMV-induced monocytetransendothelial migration (Fig. 2 ) and total migration (Fig. 3 , A and B) occur through a PI(3)K-dependent signaling pathway.
PI(3)K is required for HCMV-mediated monocyte motility
Increased cell motility promotes monocyte migration following firm adhesion by allowing the monocytes to "squeeze" between adjacent endothelial cells and by subsequently moving in an amoeboid manner into the subendothelial space [57, 58] . Based on our findings that PI(3)K activity is required for HCMV-induced monocyte diapedesis and total migration, we next examined if HCMV infection up-regulates monocyte motility through a PI(3)K-dependent mechanism. F-actin stains were performed at 24 h postinfection, and monocytes were examined for lamellipodium formation, a hallmark of cell motility. DMSO-pretreated HCMV-infected monocytes (Fig. 4, A  and B) and the positive-control, PMA-treated monocytes (Fig.  4, I and J) exhibited pronounced lamellipodium formation, and mock-infected monocytes treated with DMSO exhibited a rounded morphology with staining of cortical actin rings and no lamellipodium formation (Fig. 4, E and F) . Approximately 95% of HCMV-infected and PMA-treated monocytes exhibited a motile monocyte morphology, and ϳ95% of mock-infected monocytes exhibited a nonmotile monocyte morphology in these assays (data not shown). In contrast, HCMV-infected monocytes pretreated with LY294002 (50 M) only exhibited a rounded, nonmotile phenotype (Fig. 4C ) similar to mockinfected monocytes and LY294002-pretreated (50 M), mockinfected monocytes (Fig. 4G) , suggesting that PI(3)K activity is required for HCMV induction of actin reorganization and lamellipodium formation. Like HCMV-infected monocytes, PMA-treated monocytes also lost the motile cell morphology following LY294002 (50 M) pretreatment (Fig. 4K) . As a negative control for nonmotile monocyte morphology, HCMVinfected (Fig. 4D) , mock-infected (Fig. 4H) , and PMA-treated (Fig. 4L ) monocytes were treated with cytochalasin D, an inhibitor of actin polymerization, for 30 min before cell fixation. Although LY294002-pretreated mock-infected and LY294002-pretreated HCMV-infected monocytes exhibited a significant decrease in cell size and spreading, LY294002 treatment did not affect cell viability at 24 and 48 h posttreatment (data not shown).
To quantitatively evaluate changes in cell motility, phagokinetic track motility assays were performed. This assay works on the premise that colloidal gold particles loosely bound to a gelatin layer adhere to cells as they move about the gelatincoated coverslip, thus providing a permanent record of their , mock-infected, or treated with PMA (10 ng/ml), and subsequently, were labeled with CellTracker Green. Labeled monocytes were added to cell-culture inserts containing confluent monolayers of HMECs. The ratios of cells undergoing diapedesis versus those cells that were stationary at the monolayer surface were determined by fluorescence microscopy after a 24-h incubation. Results are plotted as mean Ϯ SD of 15 random fields of view (200ϫ original magnification) from three separate experiments using different human blood donors. The HCMV-infected and PMA-treated groups are significantly different from the mock-infected, LY294002-pretreated mock-infected, LY294002-pretreated HCMV-infected, and LY294002-pretreated PMAtreated groups (PϽ0.01). movement. At 6 h postadhesion, cell track areas were measured (arbitrary units) for HCMV-infected (DMSO; Fig. 5A ), LY294002-pretreated (50 M) HCMV-infected (Fig. 5B) , cytochalasin D-pretreated HCMV-infected (Fig. 5C ), mock-infected (DMSO; Fig. 5D ), LY294002-pretreated (50 M) mockinfected (Fig. 5E) , cytochalasin D-pretreated mock-infected (Fig. 5F ), PMA-treated (Fig. 5G) , LY294002-pretreated PMAtreated (Fig. 5H) , and cytochalasin D-pretreated PMA-treated (Fig. 5I ) monocytes, and the average track area per cell of 50 monocytes was determined for each experimental arm. Singlecell tracks for each experimental arm are represented at 400ϫ original magnification. PMA-treated monocytes and DMSOtreated HCMV-infected monocytes moved over a surface area approximately five times greater than DMSO-treated mockinfected monocytes (Fig. 5J) . Mock-infected, PMA-treated, and HCMV-infected monocytes pretreated with LY294002 exhibited a significant reduction (PϽ0.01) in area traveled when compared with their DMSO-treated counterparts (Fig. 5J) . Likewise, the pretreatment of monocytes with cytochalasin-D as a negative control significantly reduced (PϽ0.01) HCMVinfected and PMA-treated monocyte motility (Fig. 5J) . HCMVinfected monocytes pretreated with wortmannin, an alternative PI(3)K inhibitor, exhibited a nonmotile cell morphology and exhibited a quantitative decrease in monocyte motility similar to LY294002-pretreated HCMV-infected monocytes in the colloidal gold motility assay, thus confirming the role of PI(3)K in promoting HCMV-infected monocyte motility (data not shown). Together, these data indicate that PI(3)K activity is used during HCMV infection to promote monocyte motility.
PI(3)K regulates HCMV-induced chemokine expression
In addition to motility, HCMV could up-regulate, in a PI(3)Kdependent manner, cellular gene products associated with other aspects of monocyte extravasation and inflammation, such as adhesion molecules, inflammatory cytokines, chemokines, and chemokines receptors. To elucidate cellular factors up-regulated by HCMV in a PI(3)K-dependent manner, we examined, by Affymetrix gene-chip array analysis, the expression profiles at 48 h postadhesion of DMSO-pretreated mockinfected, DMSO-pretreated HCMV-infected, and LY294002-pretreated HCMV-infected monocytes. To perform this experiment, we chose to examine monocytes 48 h after infection, as we hypothesized that most genes associated with migration would be up-regulated by this time-point. That is, the initiation of monocyte diapedesis, which we examined at 24 h postinfection (Fig. 2) , would have occurred, and complete migration (Fig. 3) would be underway. Table 1 lists gene products with known relevance to migration and inflammation that were up-regulated more than twofold in expression by DMSO-pretreated HCMV-infected monocytes compared with DMSO-pretreated mock-infected monocytes and were down-regulated twofold or greater in LY294002-pretreated HCMV-infected monocytes compared with DMSO-pretreated HCMV-infected monocytes. Only those gene products that met these criteria in two independent experiments using monocytes isolated from different human blood donors were included in this table. Although two adhesion molecules were induced by HCMV infection in a PI(3)Kdependent manner, these analyses revealed that the majority of genes related to migration and inflammation, which were upregulated by HCMV-induced PI(3)K activation, were chemokines and chemokine receptors ( Table 1) .
The up-regulation of chemokines by HCMV infection could have proatherosclerotic effects by activating and recruiting additional monocytes and T cells into the vessel lumen. In fact, MCP-1, MCP-2, MCP-3, GRO-␣, and ELC have been implicated in atherogenesis [59 -66] . These chemokines could also assist in viral dissemination by recruiting additional leukocytes to sites of infection, where they then could be infected, or by amplifying the migration of HCMV-infected monocytes. Proinflammatory cytokines produced by activated monocytes and macrophages in plaques also play a pivotal role in promoting atherogenesis as discussed above [33, 34, 39 -44, 46, 47, 59] . Although a number of proatherosclerotic cytokines were induced greater than twofold by HCMV infection, including interleukin (IL)-1␤, tumor necrosis factor ␣, IL-6, IL-12, and IL-15, their expression was not consistently altered by LY294002 pretreatment (data not shown). These data suggest that although HCMV-induced PI(3)K activation is pivotal in mediating many aspects of HCMV-induced migration and inflammation, other cellular signaling pathways are involved.
To confirm the up-regulation of chemokine expression by HCMV-induced PI(3)K activation, RNase protection assays were preformed on RNA harvested from DMSO-pretreated mock-infected, LY294002-pretreated mock-infected, DMSO-pretreated HCMV-infected, and LY294002-pretreated HCMV-infected monocytes using the hCM-8 human cytokine multiprobe template set (BD Biosciences; Fig. 6A ). Band intensities were analyzed using Quantity One image analysis software (Bio-Rad), normalized to the respective L32 band intensities, and plotted in arbitrary units (Fig. 6B) . Consistent with our gene-chip array data (Table 1) , these analyses revealed that MCP-1, MCP-2, MCP-3, HCC-1, and MIP-1␣ were dramatically up-regulated by HCMV infection in two experiments using monocytes purified from different human blood donors (Fig. 6B) . Of these chemokines, MCP-1, MCP-2, MCP-3, and HCC-1 exhibited a twofold or greater decrease in HCMV-infected monocytes that were pretreated with LY294002 (50 M) prior to infection (Fig. 6B) . MIP-1␣ was reduced twofold or greater in LY294002-pretreated HCMV-infected monocytes from Donor 2 but exhibited a less-than-twofold reduction in LY294002-pretreated HCMV-infected monocytes from Donor 1 (Fig. 6B) . This finding is consistent with our gene-chip array experiments in which we found that MIP-1␣ expression was up-regulated greater than twofold in HCMV-infected monocytes in two independent experiments using monocytes isolated from different human blood donors and was reduced in expression by twofold or greater in LY294002-pretreated HCMV-infected monocytes in only one of these experiments (data not shown). These findings suggest that like many of the inflammatory cytokines induced by HCMV infection, additional signaling pathways regulate MIP-1␣ expression. Together, our analyses show a role for HCMV-induced PI(3)K activation in promoting chemokine and chemokine receptor expression and are consistent with our proposed roles of HCMV-infected monocytes as vectors for viral dissemination and promoters of inflammatory disease. This study sets the stage for future studies on the regulation of additional inflammatory mediators induced by HCMV infection of monocytes.
DISCUSSION
Macrophages are believed to be sites of persistent infection in host tissue [15] . Infected macrophages have been found in nearly every organ in patients with HCMV disease [15] [16] [17] and are found in the tissue of healthy, seropositive hosts [67] . Furthermore, the appearance of infected tissue macrophages corresponds temporally with viremia in the host [15] [16] [17] [18] [19] . These findings have led to the hypothesis that monocytes infected during viremia serve as a Trojan horse for widespread tissue dissemination and the establishment of HCMV persistence.
There have been several obstacles, however, in determining the role monocytes play in dissemination during HCMV infection. First, HCMV infection is limited to human cells, and there are no animal models for directly studying HCMV pathogenesis, although animal models studying the related murine and rat CMVs do exist [29 -32] . Second, monocytes are nonpermissive for viral gene expression and replication following a primary infection in vitro [28, 68 -71] . Studies have shown, however, that macrophages, which have been differentiated in vitro from monocytes using certain stimuli, become productive for viral replication only after differentiation [68 -71] .
To address this seeming paradox, we have developed a novel system to examine changes induced by HCMV infection in human primary peripheral blood monocytes cultured in vitro [28] . We recently showed that HCMV infection of monocytes drives monocyte-transendothelial migration and their differentiation into macrophages and that these HCMV-differentiated macrophages begin to replicate the original HCMV following this differentiation event [28] . Furthermore, we showed through the use of UV-inactivated HCMV that HCMV-induced differentiation and migration occurred in the absence of viral gene expression [28] , suggesting that HCMV exerts these events through activation of cellular signal-transduction pathways. This makes biological sense, as HCMV cannot express viral gene products or replicate until the infected monocytes differentiate into macrophages. We proposed, therefore, that HCMV upon infection initiates a cellular signal-transduction event and subsequently induces cellular changes in monocytes conducive to replication and spread [28] . Widespread viral dissemination to host organs through monocytes correlates with the multiple organ system involvement and the severe disease associated with HCMV infection of the immunocompromised [15, 72] . In immunocompetent hosts, the aberrant induction of monocyte migration following infection could exacerbate inflammatory diseases such as atherosclerosis. Further supporting this concept, we reported that HCMV-differentiated macrophages have an inflammatory macrophage phenotype at 2 weeks postinfection [28] . Together, our initial study suggests that HCMV-induced monocyte activation is critical for the viral lifecycle and that as a consequence of this viral strategy of dissemination, this activation event also plays a role in the pathogenesis of HCMV-mediated diseases.
To understand this critical step of monocyte activation, our laboratory has been investigating the cellular signaling-transduction pathways responsible for HCMV-induced monocyte activation. In this study, we first showed that HCMV infection of monocytes resulted in increased PI(3)K activity. This increase in PI(3)K activity in monocytes is the first evidence of this pathway being altered in cells relevant to in vivo HCMV infection. The finding is consistent with a study by Johnson et al. [73] , showing that HCMV up-regulates PI(3)K activity in HEL fibroblasts, although they did not examine the functional consequences of increased PI(3)K activity at the cellular level. However, they did show that PI(3)K activity was required for viral replication in HEL fibroblasts [73] . As HCMV does not replicate in monocytes, we proposed that the HCMV-induced PI(3)K activation in monocytes was likely a critical mediator in other aspects of monocyte infection.
We next addressed the potential biological significance of the induced PI(3)K activity and showed that HCMV promotes monocyte diapedesis at 24 h postinfection and total migration through the endothelial monolayer and the transwell insert at 96 h in a PI(3)K-dependent manner. When PI(3)K was blocked before HCMV infection with the PI(3)K-specific drug inhibitor LY294002, levels of diapedesis and total migration returned to levels comparable with mock-infected monocytes. These data indicate that the up-regulation of PI(3)K activity by HCMV is central to the viral induction of monocyte migration. Therefore, we next examined if HCMV-induced PI(3)K activation promotes migration through the up-regulation of monocyte motility. HCMV-infected monocytes exhibited lamellipodium and retractile tail formation, characteristic of a motile cell phenotype. In contrast, infected monocytes pretreated with LY294002 before infection exhibited a nonmotile cell phenotype similar to mock-infected monocytes, which was characterized by cortical actin ring-staining and an absence of pseudopodium and lamellipodium. Quantification of cell motility using the phagokinetic track assay confirmed that PI(3)K activity was required for HCMV-induced monocyte motility. Consistent with our findings, previous studies have shown that chemokines promote monocyte migration in a PI(3)K-dependent manner through the up-regulation of cell motility [54, 55] , although in our studies, we did not add chemokines to the monocytes. Monocytes were treated with only HCMV, and at early times post-infection, PI(3)K activity was regulated by the effect of HCMV alone. Based on our gene chip-array data, it is possible that at later times postinfection, the release of chemokines by infected monocytes could, in an autoregulatory manner, enhance PI(3)K activity and thus amplify monocyte migration.
To elucidate additional roles that HCMV-induced PI(3)K activation might play in monocyte migration and inflammatory mediator production, we performed gene-chip array analyses on mock-infected, HCMV-infected, and LY294002-pretreated HCMV-infected monocytes at 48 h postadhesion. Because of their role in migration, we expected to see the up-regulation of a multitude of adhesion molecules by HCMV in a PI(3)Kdependent manner in our gene-array analyses. However, only two adhesion molecules were up-regulated by HCMV in a This table represents those genes related to migration and inflammation that were up-regulated in expression by twofold or greater in HCMV-infected monocytes (DMSO) compared with mock-infected monocytes (DMSO) and that were reduced in expression by twofold or greater in LY294002-pretreated HCMV-infected monocytes compared with DMSO-pretreated HCMV-infected monocytes. Only gene products that met these criteria in two separate experiments using different human blood donors are shown.
b Methods for gene-chip analyses can be found in Materials and Methods and Results. c This fold increase represents the increase of gene-product expression in DMSO-pretreated HCMV-infected monocytes compared with DMSO-pretreated mock-infected monocytes.
d This fold decrease represents the decrease of gene-product expression in LY294002-pretreated HCMV-infected monocytes compared with DMSO-pretreated HCMV-infected monocytes.
e mRNA RefSeq represents the National Center for Biotechnology Information mRNA reference sequence. MCP-1, Monocyte chemoattractant protein-1; GRO-␣, growth-related oncogene-␣; ELC, Epstein-Barr-induced 1 ligand chemokine; CCR1, chemokine receptor 1; MIP-1␣, macrophage-inflammatory protein-1␣; RANTES, regulated on activation, normal T expressed and secreted; MPIF-1, myeloid progenitor inhibitory factor-1; CCRL2, CCR ligand 2; Mac-2 BP, membrane-activated complex-2 binding protein.
PI(3)K-dependent manner, suggesting that changes in adhesion molecule expression occur primarily at early times postinfection or that PI(3)K does not regulate the process of adhesion per se but rather regulates the process of motility. Nevertheless, an early induction of adhesion molecules would be consistent with our previous reports of HCMV-induced ␤ 1 integrin and occludin expression, which begins to occur at 4 h postinfection and plateaus by 24 h postinfection [28] . We are currently addressing the regulation of HCMV-induced adhesion molecule expression by PI(3)K activation in monocytes at early times postinfection. The gene-chip array study and the RNase protection assays did reveal a PI(3)K-dependent induction of multiple chemokines by HCMV infection. As discussed in Results, these chemokines are known to promote atherogenesis through activation of the cellular components of the plaques or through the recruitment of additional monocytes and T cells Fig. 6 . HCMV infection induces chemokine expression in a PI(3)K-dependent manner. DMSO-pretreated mock-infected, LY294002-pretreated mock-infected, DMSO-pretreated HCMV-infected, and LY294002-pretreated HCMV-infected monocyte RNA from two independent experiments using different human blood donors was hybridized with an [␣ 32 P]UTP-labeled hCM-8 template set (BD Biosciences) and subjected to RNase protection assays using the Multi-Probe RNase protection assay system (BD Biosciences) according to the manufacturer's protocol (A). Band intensities were determined using Quantity One image analysis software (Bio-Rad), normalized to the respective L32 band intensities, and plotted in arbitrary units (B). HCC-1, Hemofiltrate CC chemokine 1. into the plaque [59 -66] . Such a chemokine-induced monocyte recruitment event could also play a role in recruiting additional infected monocytes into host tissue or promoting the recruitment of more monocytes to serve as targets for viral infection in the tissue. This initial project sets the stage for additional studies in which we will investigate HCMV-induced changes in monocytes that are known to promote inflammation and atherogenesis. Currently, we are investigating whether HCMV-induced chemokine expression promotes leukocyte and lymphocyte migration directly.
Altogether, these results support our hypothesis that viralmediated cellular activation is the driving force behind HCMV-induced monocyte migration. This study demonstrated that HCMV infection activated PI(3)K in monocytes and that PI(3)K was essential for HCMV-induced monocyte-transendothelial migration. Additionally, we provided evidence that the viral induction of PI(3)K results in inflammatory mediator expression, which could have additional pathological consequences for the host. By deciphering the cellular pathways usurped during HCMV infection, we hope to provide an understanding of the steps necessary for viral infection and thus, the identification of new target sites for therapeutic intervention.
